Skip to main content

Advertisement

Table 3 Clinical trials with BTK-inhibitors in solid tumors

From: Role of Bruton’s tyrosine kinase in B cells and malignancies

BTK-inhibitor Tumor Type Treatment combination Phase Trial Status NCT#
Ibrutinib Pancreatic Cancer nab-paclitaxel and gemcitabine ll/lll Ongoing, Not Recruiting NCT024B6668
Ibrutinib Pancreatic Cancer nab-paclitaxel and gemcitabine I Recruiting NCT02562898
Ibrutinib Renal/Urethelial/Gastric/Colorectal Cancer chemotherapy/small molecule Ib/II Recruiting NCT02599B24
Ibrutinib HER2/MYC + Oesophageal Cancer   I Recruiting NCT02884453
Ibrutinib EGFR + Non-small Cell Lung Cancer (NSCLC)   I/ll Ongoing, Not Recruiting NCT02321540
Ibrutinib NSCLC/Breast Cancer/Pancreatic Cancer Durvalumab (anti-PD-L1) I/ll Completed NCT02403271
Ibrutinib Pancreatic Neuro-endocrine tumors (pNET) /metastatic Carcinoid   II Recruiting NCT02575300
Ibrutinib Stage IV Cutaneous Melanoma   II Recruiting NCT02581930
Ibrutinib Metastatic Renal Cancer Nivolumab (anti-PD-L1) lb./ll Recruiting NCT02899078
Ibrutinib Localized Prostate Cancer   I/II Recruiting NCT02643667
Acalabrutinib Advanced/Metastatic Pancreatic Cancer Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02362048
Acalabrutinib Recurrent Ovarian Cancer Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02537444
Acalabrutinib Glioblastoma   lb/ll Recruiting NCT02586857
Acalabrutinib NSCLC Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02448303
Acalabrutinib Head and Neck Squamous Cell Carcinoma (HNSCC) Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02454179
Acalabrutinib Platinum-resistant Urethelial (Bladder) Cancer Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02351739,